Safety Issues Clinical Trial
Official title:
Propofol Sedation of More Than 200 mg Enables Patients to Drive Home After Outpatient Colonoscopy Including Colorectal Polypectomy
This study examines that the use of >200 mg of propofol sedation enables patients to drive home safely after outpatient colonoscopy.
The hospital policy of routine discharge to normal activity 1 hour after propofol mono-sedation for EGD or colonoscopy was approved by the ethics committee of Showa Inan General Hospital in January, 2004 (http://www.sihp.jp). The investigator' s subsequent experience verified the safety of this discharge policy which was reconfirmed in March 2014. Based on these studies, the upper limit of 200 mg was established for those allowed early discharge and driving to home. This study examines that the use of >200 mg of propofol sedation enables patients to drive home safely after outpatient colonoscopy. ;
| NCT number | NCT05213208 |
| Study type | Observational [Patient Registry] |
| Source | Showa Inan General Hospital |
| Contact | Akira Horiuchi, MD |
| Phone | 09021684311 |
| [email protected] | |
| Status | Recruiting |
| Phase | |
| Start date | January 16, 2022 |
| Completion date | December 31, 2022 |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04485481 -
Single and Multiple Ascending Dose Study of ADX-914 in Healthy Adult Volunteers
|
Phase 1 | |
| Completed |
NCT03473236 -
Phase 1A Safety Trial of Inhaled PK10571 (GB002)
|
Phase 1 | |
| Not yet recruiting |
NCT03683953 -
The Treatment of Bronchopulmonary Dysplasia by Intratracheal Instillation of Mesenchymal Stem Cells
|
Phase 1 | |
| Recruiting |
NCT05112159 -
Study of IPG1094 in Healthy Participants
|
Phase 1 | |
| Completed |
NCT04335045 -
Phase I Study of PH100 (Ecklonia Cava Phlorotannins)
|
Phase 1 | |
| Recruiting |
NCT05037227 -
Safety Profile Following Inactivated COVID-19 Vaccine in Healthy Adults Aged >18 Years in Indonesia
|
||
| Recruiting |
NCT05068947 -
Safety, Tolerability, and Pharmacokinetic Study of Single Ascending Dose of GV101 in Healthy Subjects
|
Phase 1 | |
| Recruiting |
NCT04573049 -
The Effectiveness and Safety of Levosimendan in Patients With Severe Aortic Stenosis and Heart Failure Undergoing Transcatheter Aortic Valve Replacement
|
Phase 4 | |
| Completed |
NCT04188821 -
Reduction of Seroma and Improvement of QoL in Breast Reconstruction With Tissue Expander
|
N/A | |
| Completed |
NCT03667430 -
Safety Evaluation of Porous Silica in Men
|
N/A | |
| Completed |
NCT04499482 -
Safety and Tolerability of Soy Fiber
|
N/A | |
| Completed |
NCT03141905 -
Sick-Day Protocol to Improve Outcomes in Chronic Kidney Disease
|
N/A | |
| Completed |
NCT05244161 -
A Quasi-experimental Evaluation of the Malezi Program in Tanzania
|
N/A | |
| Recruiting |
NCT03791372 -
Clinical Effect and Safety of Autologous Umbilical Cord Blood Transfusion in the Treatment of Cerebral Palsy
|
Phase 1 | |
| Withdrawn |
NCT04759066 -
The HEALiX™ Intubated Patient (IP) Pilot Study
|
N/A | |
| Not yet recruiting |
NCT04774900 -
Standardization of Ambulance Equipment
|
||
| Active, not recruiting |
NCT04690725 -
TQB3525 for Advanced Bone Sarcomas With PI3KA Mutations or PTEN Loss
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04002440 -
Directed Use of REmote Patient Management System AMia to Achieve Prescribed Dry Weight
|
N/A | |
| Terminated |
NCT03585192 -
Safety of Immediate Skin-to-Skin Contact After Vaginal Birth in Vigorous Late-Preterm Neonates
|
N/A | |
| Completed |
NCT03157414 -
Empagliflozin in Renal Transplant Recipients
|
Phase 4 |